secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zymeworks Inc. (ZYME)
CIK:        0001937653
Form:       8-K
Filed at:   2026-09-23T20:06:24+00:00
Accession:  0001193125-26-399383
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 1.01, 2.01, 2.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zymeworks closes $17/share Theravance acquisition; issues $350M notes
---------------------------------------------------------------------

- Zymeworks completes Theravance merger; each share converted to $17.00 cash plus one CVR.
- CVR pays 80% of ampreloxetine license proceeds, $50M U.S./EU first-commercial-sale milestone, 10% net sales.
- Issued $350M senior secured notes at 8.25% fixed rate, maturing Dec 31, 2036, to OMERS-affiliated purchaser.
- Notes guaranteed by four Theravance IP subsidiaries; proceeds funded cash consideration and CVR payments.
- Investor call scheduled Sept 28, 2026, 8:30 a.m. ET to discuss closing details.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937653/000119312526399383/0001193125-26-399383-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937653/000119312526399383/d270232d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-399383

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer